Genetic Technologies Limited announces the start of testing operations in the United States for its revolutionary geneType? genetic risk assessment product series. GeneType?s multi-patented, clinically validated tests will now be performed by Gene by Gene, a premier specialty genetic laboratory based in Houston, Texas, a state-of-the-art, highly accredited laboratory (CLIA, CAP, AABB and CDPH licensed).

Gene by Gene?s ability to process up to 25,000 tests per month greatly increases geneType?s operational capacity in North America. The lab?s location in central US will also shorten the turn-around time for samples sent in from North America. Together with the company?s recent distribution agreement with health and wellness technology leader Stay Healthy Inc. (?Stayhealthy?), geneType is poised for exponential growth across North America.

Stemming from its significant contributions to the Human Genome Project nearly 20 years ago, GTG pioneered and patented the burgeoning area of genetic testing known as polygenic risk score (PRS). By combining PRS with clinical risk models, the company has refined a suite of integrated genetic testing and assessment tools designed to assess an individual?s risk for serious disease and ultimately enable actionable recommendations to help mitigate that risk. Since the first geneType assessment for breast cancer was developed, in 2022 after 20 years of research, the company has developed a Multi?Risk test which is a comprehensive suite of the most innovative tests for nine specific diseases (as one non-invasive cheek swab) evaluating risk for metabolic, cardiovascular, and oncological diseases, covering 70 percent of annual mortality and morbidities.

Clinical-grade assessments for new cancers and chronic conditions are in development. GeneType?s non-invasive, saliva-based tests are clinically validated and regulatory approved. Stayhealthy?s partnership with geneType will bring geneType?s innovative suite of tests to a broader consumer base through employee health benefits and online pharmacy channels across the US and Canada.

In 2023, Stayhealthy launched a Direct to Consumer (DTC) online discount pharmacy card and website with access of up to 1.5 million users and a Business to Business to Consumer (B2B2C) with Level 5 Section 125 (cafeteria) plan for employers and workers. With a database of over 200 million U.S. email addresses, Stayhealthy is well-positioned to promote geneType?s portfolio of personalized health risk assessments across North America.